This post was originally published on this site Sadly, millions of people in the U.S. live with Alzheimer’s disease. Even sadder is that fewer than half of Alzheimer’s patients or their caregivers report being told of the diagnosis by a healthcare provider. An Alzheimer’s Association report from 2015 indicated that only 45 percent of people…
Conditions
Conditions
Inaugural Rainwater Prize Winners Focus on Alzheimer’s and Other Brain Research
This post was originally published on this site An eminent Alzheimer’s disease (AD) scientist, Michel Goedert, and an early career genomic engineering investigator, Patrick Hsu, are inaugural winners of the Rainwater Prize Program that acknowledges leading work in brain research. Such work includes groundbreaking efforts to advance new treatments for neurodegenerative disorders, including Alzheimer’s, that are associated with tau protein accumulation…
FDA Supports Use of Anti-diarrheal Medications with Nerlynx
This post was originally published on this site The U.S. label of Nerlynx (neratinib), a treatment for early stage HER2-positive breast cancer, now includes information on the use of two anti-diarrheal medications to prevent severe side effects of the therapy. Puma Biotechnology, which markets Nerlynx, received approval from the U.S. Food and Drug Administration (FDA) to include…
Keytruda Survival Benefits Similar to Chemo for Relapsed Mesothelioma, Phase 3 Trial Finds
This post was originally published on this site Treatment with the immunotherapy Keytruda (pembrolizumab) appears to be as effective as conventional chemotherapy for treating malignant pleural mesothelioma patients who relapse after one course of platinum-based chemotherapy, data from a Phase 3 trial show. Although more of these advanced cancer patients responded to Keytruda than to…
Unusual Case of Tears in Heart Blood Vessels Found in Cardiac Sarcoidosis Patient
This post was originally published on this site Tears in blood vessels of the heart can occur in people with cardiac sarcoidosis, a case report found, although the incidence of this complication appears to be low. The report, “Spontaneous coronary artery dissection in cardiac sarcoidosis,” was published in Oxford Medical Case Reports. Spontaneous coronary artery dissection…
I-Mab Expands its Ongoing Myeloma Clinical Trials of MOR202 to China
This post was originally published on this site I-Mab Biopharma is expanding to mainland China its ongoing clinical studies assessing MorphoSys‘ investigational antibody therapy MOR202 (TJ202) as treatment for people with multiple myeloma, the company announced. The decision comes after an Investigational New Drug clearance issued by China’s National Medical Products Administration (NMPA). The ongoing…
Trabectedin, Bevacizumab, Platinum Chemotherapy Combo May Work, But Safety a Concern, Study Finds
This post was originally published on this site Women with ovarian cancer who are partially sensitive to platinum-based chemotherapy may benefit from a new combination therapy — but safety concerns need to be addressed first, a study suggests. The new study proposes a combination of trabectedin and bevacizumab with platinum-based chemotherapy for these patients, whose disease…
Targeted Radiation (SBRT) Can Control Prostate Cancer That Has Spread Slightly, Trial Results Suggest
This post was originally published on this site Stereotactic body radiation therapy (SBRT) — a form of targeted, high-dose radiation therapy — significantly extends the time without detectable disease progression when given to prostate cancer patients with limited metastatic lesions, data from a Phase 2 trial show. These findings were presented at the recent 2019 American…
New Blood Test May Help Detect Beta-Amyloid Plaques in People at Risk of Alzheimer’s, Study Shows
This post was originally published on this site Scientists have developed a simple blood test that may help clinicians identify whether a person has accumulations of abnormal amyloid protein deposits in the brain — an event linked to an Alzheimer’s diagnosis. This new laboratory test may represent an alternate diagnostic tool to other expensive brain…
Copiktra Superior to Arzerra for CLL/SLL Patients with Prior Therapies, Data Suggest
This post was originally published on this site Treatment with Copiktra (duvelisib) doubles response rates compared with Arzerra (ofatumumab), and significantly extends the time until disease progression or death in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two previous therapies, a Phase 3 trial revealed. The…
Dementia Phone Service Provider teleCalm Wins $100K Prize for Start-up Development
This post was originally published on this site Landline-style phone service provider teleCalm will use a $100,000 award to advance its new phone service for dementia patients, which helps keep people with Alzheimer’s and related conditions safely connected with family and friends. The Diamond Award was presented by the Austin, Texas offices of MassChallenge, a U.S.-based…
Seattle Genetics’ Tucatinib Extends Survival Outcomes in Metastatic HER2-positive Breast Cancer Patients, Phase 2 Trial Shows
This post was originally published on this site People with HER-positive advanced breast cancer who received multiple HER-targeted therapies have significantly better survival outcomes — including overall survival and survival without disease progression — when given a combination of Seattle Genetics‘ tucatinib plus standard trastuzumab and Xeloda (capecitabine), results from a Phase 2 trial show.…